WuXi Biologics, a contract biologics manufacturer, has started a 10-year, $1.4-billion investment plan to expand the company’s research, development, and large-scale drug-substance and drug-product manufacturing capacity and capabilities in Singapore.

The investment will establish a contract research, development, and manufacturing center in Singapore, including a research and development service center and large-scale drug-substance and drug-product manufacturing facilities for biologics.

The new site will add 120,000 L of biomanufacturing capacity by 2026 to WuXi Biologics’ network and is anticipated to employ 1,500 research, development and manufacturing staff when complete.

Source: WuXi Biologics